Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Orio

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Cancer|March 13, 2016
National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base studyBrandon A Mahal, Yu-Wei Chen, Jason A Efstathiou, et al.
Brachytherapy|January 15, 2019
A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancerMartin T King, David D Yang, Vinayak Muralidhar, et al.
Urologic Oncology|December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancerMartin T King, Ming-Hui Chen, Brian J Moran, et al.
Cancers|April 13, 2024
Prognostic Significance of the Cribriform Pattern in Prostate Cancer: Clinical Outcomes and Genomic AlterationsMutlay Sayan, Yetkin Tuac, Mahmut Akgul, et al.
International Journal of Molecular Sciences|August 29, 2024
Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate CancerMutlay Sayan, Yetkin Tuac, Mahmut Akgul, et al.
Brachytherapy|January 15, 2019
Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapyMartin T King, Paul L Nguyen, Ninjin Boldbaatar, et al.
Cancers|May 25, 2024
Histologically Overt Stromal Response and the Risk of Progression after Radical Prostatectomy for Prostate CancerMutlay Sayan, Yetkin Tuac, Samet Kucukcolak, et al.
The Journal of Urology|April 14, 2012
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortalityYolanda D Tseng, Ming-Hui Chen, Clair J Beard, et al.
Urology|September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Brachytherapy|November 2, 2020
The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assuranceSteven J Frank, Firas Mourtada, Juanita Crook, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Cancer|March 13, 2016
National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base studyBrandon A Mahal, Yu-Wei Chen, Jason A Efstathiou, et al.
Brachytherapy|January 15, 2019
A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancerMartin T King, David D Yang, Vinayak Muralidhar, et al.
Urologic Oncology|December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancerMartin T King, Ming-Hui Chen, Brian J Moran, et al.
Cancers|April 13, 2024
Prognostic Significance of the Cribriform Pattern in Prostate Cancer: Clinical Outcomes and Genomic AlterationsMutlay Sayan, Yetkin Tuac, Mahmut Akgul, et al.
International Journal of Molecular Sciences|August 29, 2024
Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate CancerMutlay Sayan, Yetkin Tuac, Mahmut Akgul, et al.
Brachytherapy|January 15, 2019
Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapyMartin T King, Paul L Nguyen, Ninjin Boldbaatar, et al.
Cancers|May 25, 2024
Histologically Overt Stromal Response and the Risk of Progression after Radical Prostatectomy for Prostate CancerMutlay Sayan, Yetkin Tuac, Samet Kucukcolak, et al.
The Journal of Urology|April 14, 2012
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortalityYolanda D Tseng, Ming-Hui Chen, Clair J Beard, et al.
Urology|September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Brachytherapy|November 2, 2020
The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assuranceSteven J Frank, Firas Mourtada, Juanita Crook, et al.
Pageof 9